SARDH在肿瘤浸润T细胞中的关键调控作用
今天和大家分享的是2025年8月发表在Cellular & Molecular Immunology (IF: 19.8) 的一篇文章。《SARDH in the 1-C metabolism sculpts the T-cell fate and serves as a potential cancer therapeutic target》。本研究系统性地探讨了线粒体代谢酶SARDH在调控T细胞功能及其在肿瘤免疫治疗中的潜在作用。
https://www.nature.com/articles/s41423-025-01331-5
本研究揭示了线粒体碳代谢酶SARDH在肿瘤浸润T细胞中的关键作用,发现其通过调控肌氨酸-SAM代谢流影响H3K79me2表观遗传修饰,从而抑制NF-κB信号通路活性。实验证实靶向SARDH可显著增强T细胞活化、增殖、细胞因子产生和肿瘤杀伤能力,而肿瘤微环境中积累的肌氨酸通过反馈环路上调SARDH表达,加剧T细胞功能抑制。该研究为通过代谢干预增强肿瘤免疫治疗提供了新靶点和新策略。
一、研究背景
肿瘤免疫治疗尤其是免疫检查点阻断疗法,在某些癌症类型中取得了显著成功,但总体响应率有限,肿瘤微环境(TME)诱导的T细胞功能耗竭是主要障碍。
T细胞代谢重编程在决定其功能和命运中扮演关键角色,被视为"第四信号",而线粒体作为代谢中心,其功能变化与T细胞耗竭密切相关。
一碳代谢(1-C metabolism)在核苷酸合成和甲基化反应中起核心作用,但在T细胞功能调控中的作用尚未系统阐明。
二、研究意义与创新点
1、首次发现SARDH是T细胞功能的关键代谢检查点,其在耗竭T细胞中特异性高表达;
2、提出全新的"代谢-表观遗传-免疫信号"调控轴:SARDH-肌氨酸-SAM-H3K79me2-NF-κB;
3、揭示肿瘤微环境代谢物调控免疫细胞功能的新机制:肌氨酸反馈诱导SARDH表达;
4、为克服T细胞耗竭提供了新的治疗策略:靶向SARDH可显著增强T细胞抗肿瘤功能。
三、研究目的
1、通过泛癌单细胞分析鉴定调控T细胞耗竭的关键代谢基因;
2、验证SARDH对T细胞多种功能的影响;
3、阐明SARDH调控T细胞功能的分子机制;
4、评估靶向SARDH在肿瘤免疫治疗中的转化潜力。
四、研究思路
五、研究方法

六、主要实验结果
1、泛癌分析显示,肿瘤浸润T细胞中的线粒体代谢基因SARDH与CD8 + T 细胞功能障碍相关
A Bar plot illustrating the number of significantly dysregulated pathways across each cancer type. B Heatmap illustrating the scaled pathway score and the number of significantly dysregulated pathways across each cancer type. C Scheme of the computational analysis workflow for screening candidate mitochondrial metabolic genes. D Three-dimensional plot showing all mitochondria-related genes with enrichment scores, exhaustion scores, and numbers of cancer types in which genes were significantly upregulated in exhausted T cells. E Bar plot showing the number of mitochondria-related genes significantly upregulated in exhausted T cells among different numbers of cancer types. F Scatterplot showing that the enrichment score and exhaustion score of mitochondria-related genes were significantly increased in all 18 collected cancer types. G UMAP plot showing SARDH expression in CD8+ T cells. H Bar plot showing log2 (fold change) values of SARDH in exhausted T cells across each cancer type. I Enzymatic reaction of sarcosine decomposition catalyzed by SARDH. The cancer type abbreviations used are as follows: BCC basal cell carcinoma, BC breast cancer, BCL B-cell lymphoma, CHOL cholangiocarcinoma, CRC colorectal cancer, ESCA esophageal carcinoma, HCC hepatocellular carcinoma, LC lung cancer, MELA melanoma, MM multiple myeloma, NPC nasopharyngeal cancer, OV ovarian cancer, PACA pancreatic cancer, RC renal carcinoma, SCC squamous cell carcinoma, STAD stomach adenocarcinoma, THCA thyroid carcinoma, UCEC uterine corpus endometrial carcinoma
2、SARDH抑制T细胞的活化、增殖和细胞毒性功能
A Bar plot illustrating the relative expression levels of SARDH in T cells treated with 4 siRNAs targeting SARDH (#1‒#4) at different sites compared with those in T cells treated with nontargeting siRNA (NT). n = 3. B Western blot analysis of SARDH expression in nontargeting control and SARDH-knockdown human T cells. Bar plot showing the densitometric analysis, which quantifies SARDH normalized to GAPDH. C Bar plot depicting the proportion of CD69-expressing cells in nontargeting control and SARDH-knockdown human CD8+ T cells. n = 3. D Bar plot showing activation-related GO terms enriched in SARDH-knockdown samples compared with nontargeting controls, with gene counts indicated within solid circles. E–G Bar plots depicting the proportions of nontargeting control and SARDH-knockdown human CD8+ T cells expressing T-cell function-related markers, including IFN-γ (E), TNF-α (F), and granzyme B (G). n = 3. H Schematics illustrating the in vitro T-cell cytotoxicity analysis. I quantified the killing efficiency and revealed the cytotoxicity of the nontargeting control and SARDH-knockdown CD8+ T cells to A375 or T2 target cells. n = 3. J‒M Representative FACS plots illustrating the percentages of TCF-1-expressing (J) and Tcm-expressing (L) nontargeting control and SARDH-knockdown human CD8+ T cells. Quantifications of the proportions of TCF-1 (K) and Tcm (M) are also presented. n = 3. N FACS histogram showing fluorescence intensity distributions in CFSE-stained nontargeting control and SARDH-knockdown human CD8+ T cells. O Relative quantification of the proliferation abilities of nontargeting control and SARDH-knockdown human CD8+ T cells. n = 3. P Bar plot showing proliferation-related GO terms enriched in the SARDH-knockdown samples compared with the nontargeting controls. The numbers on the right indicate gene counts matched to the corresponding terms. All the data from the FACS analysis are presented as the means with SDs and are representative of at least three independent experiments. All statistically significant differences were calculated via an unpaired t test
3、SARDH抑制T细胞的迁移
A Schematic of the measurement of the migration ability of human T cells via the transwell assay. B Bar plot showing the status of human T-cell migration after 24 h in both the nontargeting control and SARDH knockdown groups. n = 3. C Status of human T-cell migration after 24 h in both the control (Vec) and SARDH-overexpressing (+SARDH) groups. n = 3. D Schematics illustrating the tumor spheroid-T-cell coculture assay. E Bright-field and multispectral fluorescence imaging of a representative coculture system after 48 h of coculture with tdTomato+ MC38-OVA spheroids (red) and staining SARDH+/+ or SARDH−/− OT-1+ CD8+ T cells (green). F Scatter dot plot illustrating the infiltration of SARDH+/+ or SARDH−/− OT-1+ CD8+ T cells into MC38-OVA spheroids. n = 7. G–H Bar plots showing the relative numbers of both infiltrating (G) and noninfiltrating (H) OT-1+ CD8+ T cells with or without SARDH knockout. I Bright-field and multispectral fluorescence images after 48 h of coculture showing tdTomato+ MC38-OVA spheroids (red), OT-1+ CD8+ T cells (green) and dead cells (blue) in the SARDH+/+ and SARDH−/− groups. J Box-and-whisker plot illustrating the tumor-cell-killing abilities of SARDH+/+ or SARDH−/− OT-1+ CD8+ T cells. SARDH+/+, n = 7; SARDH−/−, n = 8. All the bar plot data are presented as the means with SDs, and all the scatter dot plot data are presented as the medians with interquartile ranges. All the data shown are representative of at least three independent experiments. All significances presented were calculated via an unpaired t test
4、T细胞中SARDH缺乏延缓了体内肿瘤进展
A Schematic illustrating the subcutaneous tumor-bearing experiments. B Tumor growth curve over days postinjection of MC38-OVA cells into WT and SARDH−/− OT-1+ mice. WT: n = 6; SARDH−/−: n = 10. C Tumor growth curve over days postinjection of MC38-OVA cells into WT and CKO OT-1+ mice. WT: n = 6; CKO: n = 4. D Representative image of tumors from WT mice and CKO OT-1+ mice used for the analysis of tumor-infiltrating T cells. E–H Box‒and‒whisker plots showing the proportions of cells expressing cell function-related markers, including IFN-γ (E), TNF-α (F), granzyme B (G), and Lamp-1 (H), among tumor-infiltrating CD8+ T cells isolated from WT and CKO mice. n = 4. I Box-and-whisker plot showing the relative quantification of CD8+ T-cell percentages in WT and CKO mouse tumors. n = 4. J Proportions of Ki67-expressing CD8+ T cells in WT and CKO mice. n = 4. K Proportions of TCF-1-expressing CD8+ T cells in WT and CKO mice. n = 4. L Schematic showing that NSG mice were inoculated with MART-1+ A375 cells and subsequently with MART-1-specific T cells at certain time points. M Tumor growth curve over days postinjection with MART-1+ A375. The arrows indicate the time points at which TCR-T cells were injected. n = 5. N Scatter dot plot illustrating the weight of tumors after injection of TCR-T cells transfected with non-targeting shRNA (shNT) or shRNA targeting SARDH (shSARDH). n = 5. All the bar plot data are presented as the means with SDs, all the growth curve data are presented as the means with SEMs, and all the scatter dot plot data are presented as the medians with interquartile ranges. All the data shown are representative of at least three independent experiments. All significances presented were calculated via an unpaired t test
5、SARDH通过代谢物调节抑制T细胞功能
6、SARDH通过甲基化依赖性NF-κB抑制调节T细胞功能
A Western blot analysis of H3 and H3K79me2 levels in human T cells. B Bar plot showing the densitometric analysis, which was used to quantify H3K79me2 levels. C Bar plot showing the NF-κB-related GO terms enriched in the SARDH-knockdown samples compared with the normal samples. The numbers in the solid circles indicate gene counts matched to the corresponding terms. D Heatmaps showing the expression levels of genes involved in NF-κB activation in four groups of nontargeting control (-NT) and SARDH knockdown (-SARDH) human CD8+ T cells. E–F Scatterplots showing the expression levels of MAP3K14 (NIK) (E) and IKBKG (NEMO) (F) in nontargeting control and SARDH-knockdown human CD8+ T cells. The significance presented was calculated via a paired one-sided t test. n = 4. G Western blot analysis of p65 and phosphorylated p65 (Ser536) levels in human T cells (12 days after cell activation). H Bar plot showing the densitometric analysis, which was used to quantify NF-κB activation (phosphorylation levels of p65). I Heatmaps showing H3K79me2 enrichment within several genes involved in NF-κB activation across four groups of nontargeting control (-NT) and SARDH knockdown (-SARDH) conditions. J Genome browser view of the IKBKG gene region via IGV. K Scatterplot showing the quantification of H3K79me2 occupancy within the IKBKG gene. The significance presented was calculated via a paired one-sided t test. n = 3. L Bar plot illustrating the percentages of human CD8+ T cells expressing TCF-1 in the nontargeting control and SARDH knockdown groups with or without the addition of QNZ. n = 3. M Bar plot depicting the percentages of human CD8+ T cells expressing granzyme B in the nontargeting control and SARDH knockdown groups with or without the addition of QNZ. n = 3. In (L, M), the data are presented as the means with SDs, and all significance values were calculated via an unpaired t test. N Western blot analysis of p65 and phosphorylated p65 (Ser536) levels in human T cells treated (WT + S) or not treated (WT) with sarcosine (12 days after cell activation). O Bar plot showing the densitometric analysis, which was used to quantify NF-κB activation. All significances presented in the bar plots were calculated via an unpaired t test. All the bar plot data are presented as the means with SDs. All the data shown are representative of at least three independent experiments
7、sarcosine积累诱导T细胞表达SARDH
A Heatmap presenting the pathway scores of the methionine cycle and folate one-carbon metabolism in multiple cancer types [32]. B Boxplot showing the METAFlux score in tumor and normal tissues. All significances presented were calculated via Wilcoxon’s test. n = 30. C–D Scatterplots showing the concentration of sarcosine in tumors and corresponding normal tissues from gastric cancer (C) or colorectal cancer (D) patients. The significance presented was calculated via a paired one-sided t test. Gastric cancer: n = 10; colorectal cancer: n = 6. E Scatterplot showing the expression levels of SARDH in samples treated with alanine or sarcosine. The significance presented was calculated via a paired one-sided t test. n = 3. F Boxplot showing the SARDH expression levels in T cells from patient-derived peripheral blood samples and tumor tissues. The significance was calculated via Wilcoxon’s test
总结
本研究系统揭示了SARDH作为T细胞功能代谢检查点的重要作用,发现了一条全新的"代谢-表观遗传-免疫信号"调控轴。研究不仅阐明了SARDH调控T细胞功能的分子机制,还揭示了肿瘤微环境中代谢物-基因表达的反馈环路,为通过代谢干预增强肿瘤免疫治疗提供了新靶点和新策略。未来研究方向包括开发SARDH特异性抑制剂、探索其与现有免疫治疗的联合方案,以及验证SARDH表达作为免疫治疗响应预测标志物的潜力。
如您有更多课题实验需求,或者您对更多热点研究感兴趣,想进一步探索、申请基金或写文章,我们将有专业编辑评估思路,提供从实验设计到实验实施、数据解读、文章/标书产出润色的一站式科研管理服务,为您科研之路保驾护航。备注“实验”可领更多福利优惠!请联系我们。

